dc.date.accessioned |
2019-01-22T20:34:49Z |
|
dc.date.available |
2019-01-22T20:34:49Z |
|
dc.date.issued |
2018 |
|
dc.identifier.issn |
0040-3660 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/147798 |
|
dc.description.abstract |
© 2018 Media Sphera Publishing Group. All rights reserved. Aim: to assess the effectiveness of mebeverine 200 mg BID in patients with post-cholecystectomy gastrointestinal spasm not requiring surgical treatment. Materials and methods. 218 patients were included in 16 clinical centers in 14 cities in Russia. All patients had post-cholecystectomy gastrointestinal spasms, not requiring surgical treatment and received mebeverine (Duspatalin®) 200 mg BID. The observational assessment period lasted from the moment of their inclusion into the study up to 6 weeks post inlusion. The therapy results were evaluated using visual analog scales (GPA and 11-point numeric rating scale) by patient self-assessment of the dynamics of spasm/discomfort and other postcholecystectomic gastrointestinal symptoms after 2 and 6 weeks of treatment. Gastrointestinal Quality of Life Index (GIQLI) was used to assess patient quality of life. Results and discussion. All 218 patients completed the 2-week mebeverine treatment course, 101 of them finished the 6-week course ("prolonged population"). Significant positive changes in the relief of abdominal pain and dyspepsia were noted as well as normalization of stool frequency and consistency. A more marked change in values was observed during prolonged (up to 6 weeks) therapy. Both 2-week and 6-week mebeverine courses led to a normalization of patient quality of life. After 6 week therapy, an effect of mebeverine on the quality of life 91% of patients was observed comparable to cholecystectomy itself, speficially related to the quality of life subscore 'symptoms'. Conclusion. The results of our study demonstrate that mebeverine (Duspatalin®) therapy leads to an effective elimination of clinical symptoms associated with post-cholecystectomy GI-spasm disorders, like abdominal pain, symptoms of dyspepsia and stooldisorders. A more marked change in values was observed during prolonged (up to 6 weeks) therapy. |
|
dc.relation.ispartofseries |
Terapevticheskii Arkhiv |
|
dc.subject |
"Odyssey" |
|
dc.subject |
Abdominal pain |
|
dc.subject |
Cholecystectomy |
|
dc.subject |
Gallstone disease (GD) |
|
dc.subject |
Mebeverine |
|
dc.subject |
PCS |
|
dc.subject |
Post-cholecystectomy spasm and disorders |
|
dc.title |
Effectiveness of Mebeverine in patients with post-cholecystectomy gastrointestinal spasm: Results of prospective observational program "odyssey" |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
8 |
|
dc.relation.ispartofseries-volume |
90 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.relation.startpage |
40 |
|
dc.source.id |
SCOPUS00403660-2018-90-8-SID85052761128 |
|